Do you have a throbbing head and feel pressure around your eyes, cheeks, or forehead? You might have a sinus headache. A sinus headache is caused by inflammation and congestion in the sinuses ...

It is often expressed as the percentage of total body weight that consists of fat and/or lean body mass. Body composition offers numerous insights into health, fitness, and nutritional status. Body ...

Many of these symptoms overlap with other conditions that aren’t related to your sinuses. These unrelated conditions include migraines, jaw grinding, or nerve problems. That’s why it’s important to ...

The Anatomy and Function of the Piriform Cortex has Properties That Predispose it to Epileptic Seizures Synonymously referred to as “piriform,” “pyriform,” and sometimes ... Odors are first detected ...

The liturgy was in Latin, no longer a common language. The faithful were virtually silent; they “heard” or “assisted” at Mass.” In Germany, the priest “read” the liturgy. Engaging ...

Mass Effect 5 is officially in the works from BioWare. First revealed back in 2020 with a brief teaser that sparked excitement among fans of the beloved sci-fi RPG, it's been some time since we've ...

Sinusitis can cause facial pressure, sinus headache, and other symptoms. Treatment may depend on the cause. A sinus infection, also known as sinusitis or rhinosinusitis, occurs when your nasal ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

But hidden at your pharmacy among the potpourri of cough drops and cold remedies, you can find a low-risk treatment that actually may help: nasal irrigation devices. Several small studies suggest ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...